BioCryst Pharmaceuticals Appoints Babar Ghias as CFO and Head of Corporate Development: A Step Towards Enhanced Growth Strategies

BioCryst Pharmaceuticals has appointed Babar Ghias as CFO to enhance growth and capital deployment strategies. Ghias has extensive experience in finance and operations within the biotech sector, particularly in rare diseases. His background includes senior positions at Paragon Biosciences and Marathon Pharmaceuticals, where he played key roles in capital raising and preparing companies for commercial launch. CEO Jon Stonehouse expressed confidence that Ghias's expertise will support BioCryst’s growth strategy and capitalize on the commercial success of their product ORLADEYO.